Management of Depression and Anorexia in End-Stage Cancer Patients

Introduction to Treatment Options

The American Society of Clinical Oncology (ASCO) recognizes mirtazapine as a clinically established appetite enhancer, with phase II studies showing improvement in appetite and weight gain in approximately one-third of cancer patients 2, 4
Mirtazapine functions as both an antidepressant and appetite stimulant, making it uniquely suited for patients with comorbid depression and anorexia 2
Depression itself is a major contributor to poor appetite in cancer patients, and treating the underlying depression may improve nutritional intake more sustainably 3

Corticosteroids like dexamethasone provide only short-term appetite stimulation (1-3 weeks) before the antianorectic effect disappears, according to the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines 1
Dexamethasone causes muscle wasting (myopathy), which directly worsens cachexia—the opposite of the desired therapeutic goal 1, 5
The European Society for Medical Oncology (ESMO) and ASCO suggest that mirtazapine's effects are sustained over time rather than transient, making it a better choice for long-term management 1, 2

The typical starting dose of mirtazapine is 15 mg daily at bedtime, with the most common side effects being somnolence, increased appetite, and weight gain—effects that may actually be beneficial in this population 2
The ESPEN guidelines recommend restricting corticosteroid use to 1-3 weeks due to rapidly diminishing benefits, and reserving dexamethasone for specific scenarios only, such as very limited life expectancy (weeks) and other symptoms that would benefit from corticosteroids 1, 5
Nutrition consultation for calorie-dense, high-protein supplementation should complement pharmacologic intervention, as recommended by the Academy of Nutrition and Dietetics 6

Both medications work better when reversible causes of anorexia are addressed: oropharyngeal candidiasis, uncontrolled pain, constipation, and nausea, according to the National Comprehensive Cancer Network (NCCN) guidelines 6
If mirtazapine proves ineffective and life expectancy extends beyond weeks, consider megestrol acetate (400-800 mg/day) as the next option, though it carries thromboembolic risk, as suggested by the ASCO guidelines 6, 7, 8